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Context: The role of dehydroepiandrosterone-sulfate (DHEA-S) in assessing the integrity of the
hypothalamic-pituitary-adrenal (HPA) axis in patients with suspected insufficiency is uncertain.
Objective: The objective of the studywas to prospectively evaluate the diagnostic value of DHEA-S
on HPA function in consecutive patients with suspected HPA insufficiency with and without pitu-
itary lesions at a tertiary referral center.
Design and Patients: In 70 consecutive patients, insulin tolerance test was accompanied by mea-
surement of basal DHEA-S. Assessment of HPA axis was based on peak cortisol response in insulin
tolerance test (normal550nmol/liter). Toaccount for theageandgenderdependencyofDHEA-S,
a z-score was calculated using age- and gender-specific reference values of the assay.
Results: Individuals with HPA insufficiency had significantly lower z-scores than thosewith normal
HPA function (1.66 vs.0.62, P 0.0001). In individuals up to 30 yr of age, a z-score of2.0 had
100% sensitivity and specificity regarding HPA function [area under receiver operating character-
istics (ROC) curve 1.00], whereas z-scores proved less useful in older individuals. In individuals with
pituitary macroadenoma, a z-score below 2.0 had 100% specificity to predict HPA insufficiency
(area under ROC curve 0.82). In the absence of a pituitary adenoma, the diagnostic value of the
z-score was reduced (area under ROC curve 0.71).
Conclusions: Individuals with HPA insufficiency have lower z-scores for DHEA-S than those with
normal HPA function. There is evidence that a z-score could be of diagnostic value in assessingHPA
integrity, especially in younger patients and patients with pituitary macroadenoma, but further
studies are needed to consolidate these findings. (J Clin Endocrinol Metab 93: 539–542, 2008)
The diagnosis of an insufficiency of the hypothalamic-pituitary-adrenal(HPA)axisremainschallenginginclinicalpractice.Basal
serum cortisol levels, although easy to measure, were found to be of
limited value (1, 2), and limitations were also reported for the short
ACTHtest (3–5).The insulin tolerance test (ITT) is therefore still con-
sidered the gold standard in assessing the integrity of the HPA axis.
However, the ITTis cumbersome, requires experiencedstaff andclose
supervision, and has several contraindications. Dehydroepiandros-
terone and its sulfate (DHEA-S) are androgenprecursors that are pro-
duced by the adrenal cortex. Their secretion is, at least partially, con-
trolled by ACTH (6). DHEA-S is secreted in a large plasma pool and
therefore exhibits a longer half-life and fewer circadian variations,
comparedwith dehydroepiandrosterone (6, 7).DHEA-S levels are in-
fluencedbyseveralfactors,mostimportantlyageandgender(6,8),and
several studies reported low DHEA-S levels in patients with docu-
mentedhypopituitarismandHPAinsufficiency(9,10).Inparticular,in
patientswith anewlydiagnosed largepituitary tumor,DHEA-S levels
appeared to be a reliable prognostic parameter for the diagnosis of
HPA insufficiency (3). In contrast, comparably little is known on the
prognostic value of DHEA-S in assessing HPA function in a mixed
population of individuals with and without a pituitary lesion.
The aimof the present studywas to prospectively evaluate the
0021-972X/08/$15.00/0
Printed in U.S.A.
Copyright © 2008 by The Endocrine Society
doi: 10.1210/jc.2007-1780 Received August 8, 2007. Accepted October 30, 2007.
First Published Online November 6, 2007
* S.F. and S.J. contributed equally to this work.
Abbreviations: DHEA-S, Dehydroepiandrosterone-sulfate; HPA, hypothalamic-pituitary-
adrenal; ITT, insulin tolerance test; ROC, receiver operating characteristic.
O R I G I N A L A R T I C L E
E n d o c r i n e C a r e — B r i e f R e p o r t
J Clin Endocrinol Metab, February 2008, 93(2):539–542 jcem.endojournals.org 539
 at Universitatsspital-Bibliothek USB on March 27, 2008 jcem.endojournals.orgDownloaded from 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
22
08
2 
| 
do
wn
lo
ad
ed
: 
8.
5.
20
16
diagnostic value of DHEA-S adjusted for age and gender in as-
sessing the integrity of the HPA axis in consecutive patients with
suspicion of HPA insufficiency at a tertiary referral center.
Subjects and Methods
Design and participants
The study started on January 1, 2003, and ended on December 31,
2006. Consecutive adult individuals with a suspicion of HPA insuffi-
ciency and without contraindications to ITT were included in the study.
Primary adrenal insufficiency was ruled out based on basal ACTH levels
and absence of clinical features. Each ITT was accompanied by a basal
measurement ofDHEA-S. All procedureswere carried out in accordance
with the local ethical guidelines, and informed consent was obtained for
each test. Testing was conducted in an ambulatory setting. Patients ar-
rived at 0800 h after an overnight fast. Glucocorticoid medication was
stoppedat least 24hbefore the ITT.Aftermeasurementof abasal glucose
value, the test was started by iv injection of 0.1–0.2 U/kg body weight
insulin (Insulin Actrapid HM; Novo Nordisk A/S, Copenhagen, Den-
mark) to induce hypoglycemia. The patients remained supine and were
constantly supervised by an experienced nurse. Testing was performed
under ECG surveillance. Samples were drawn for glucose every 15 min
for 2 h and as needed due to hypoglycemic symptoms. Samples were
drawn for cortisol at 15, 0, 30, 45, 90, and 120.
Test qualitywas defined as adequate if a plasma glucose of 2.2mmol/
liter or less was achieved and hypoglycemic symptoms (perspiration,
feelings of hunger, drowsiness) were present. Function of the HPA axis
was defined as normal if a cortisol response of 550 nmol/liter or greater
(peak level) was achieved (11, 12).
Analytical methods
Glucose was measured by the hexokinase method (HemoCue B-glu-
cose analyzer; HemoCue, A´ngelholm, Sweden). Cortisol was measured
by competitive immunoassay (Roche Modular E170; F. Hoffmann-La
Roche, Diagnostics Division, Basel, Switzerland). Serum DHEA-S was
measured by competitive chemiluminescence immunoassay (Immulite;
Diagnostic Products Corp., Los Angeles, CA).
Statistical analysis
After checking for normality, continuous outcomes were compared us-
ing Student’s t test. Pearson 2/Fisher’s exact tests were applied for com-
paringcategorical outcomes.AP0.05 signified statistical significance.To
account for the dependency of DHEA-S on age and gender, a z-score was
calculatedusingreferencecurves thatweredevelopedbyfitting twoseparate
half-normal distributions to the age and gender-specific reference ranges
provided by the assay manufacturer (13). The z-score expresses how far in
unitsof thepopulationSDameasuredvalue is fromthemeanofapopulation
with corresponding age and gender. A z-score of1 indicates that themea-
sured value is 1 SDbelow themeanof a reference populationof the sameage
and gender. The diagnostic value of the z-score in predicting the function of
HPA axis was assessed by performing receiver operating characteristics
(ROC) analyzes. To optimize comparability with earlier reports (3), three
agegroupswereprespecified:30yroryounger,31–50yr,and51yrorolder.
In addition, separate analyses were performed according to presence or
absence of pituitary adenoma. All statistical analyses were done with Stata
9.1 (Stata Corp., College Station, TX).
Results
Between 2003 and 2006, a total of 74 ITTs were performed
to assess the integrity of the HPA axis. In four cases the tests did
not fulfill the prespecified quality criteria, and these patients
were excluded from the analysis.Consequently, the present anal-
ysis was based on 70 ITTs. Baseline characteristics and indica-
tions for ITT are presented in Table 1. Whereas 35 patients had
a pituitary adenoma (31 macroadenomas, four microadeno-
mas), there were no differences in the indications for ITT be-
tween the two groups and throughout different age groups with,
in particular, a similar proportion of pituitary adenoma. A total
of 40 subjects revealed an insufficient HPA axis, defined as a
peak cortisol of less than 550 nmol/liter in response to the ITT,
whereas the HPA axis was normal in 30 subjects. Age ranged
from14 to 70 yr, and subjectswith an insufficientHPAaxiswere
TABLE 1. Patient characteristics
HPA axis insufficient
(n  40)
HPA axis normal
(n  30)
Gender (female/male) 17/23 16/14
Age (yr) (mean  SD) 47.7  12.0 39.6  13.0a
Body mass index (kg/m2) (mean  SD) 26.3  6.1 25.1  5.2
DHEA-S (g/ml) (median, interquartile range) 0.47, 0.24–0.71 1.25, 0.96–1.80a
z-score (mean  SD) 1.66  1.53 0.62  1.08a
Indications for ITT
Pituitary adenoma 22 13
Macroadenoma 21 10
Microadenoma 1 3
Other sellar tumor 4
Other pituitary disease 1
Traumatic brain injury 2
Biochemical insufficiency of other pituitary axis 3 6
Clinical features and inconclusive cortisol levelsb 10 9
Fatigue, impaired physical performance 4 5
Hypoglycemiac 3
Other 3 4
a P  0.01 for difference between individuals with insufficient and individuals with sufficient HPA axis.
b Patients with suspicion of HPA insufficiency based on personal history, symptoms, and signs, but without documented lesion to pituitary or sellar region, primary
adrenal insufficiency was excluded, cortisol levels were between 200 and 500 nmol/liter.
c Other causes for hypoglycemia were excluded before testing.
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generally older than those with a normal HPA axis (P  0.01).
In contrast, no differences in gender or body mass index were
found between the two groups. Levels of DHEA-S ranged from
0.3 to 4.8 g/liter and were significantly lower in patients with
insufficient compared with individuals with normal HPA func-
tion (median 0.47 vs. 1.25g/ml, P 0.01). Similarly, the mean
z-score adjusted for age and genderwas lower in individualswith
HPA insufficiency (1.66 vs. 0.62 for insufficient and normal
HPA axis, respectively, P  0.01).
Figure 1 shows the distribution of the age- and gender-specific
z-scores of DHEA-S for the three prespecified age groups and in-
dividuals with and without pituitary adenoma by HPA axis func-
tion. In individuals up to 30 yr old with insufficient HPA axis, the
mean z-score was significantly lower than in individuals with nor-
mal HPA function (4.03 vs. 0.38, P  0.0001). A z-score of
2.0 (i.e. 2 SD below themean of a populationwith corresponding
age and gender) perfectly predicted the outcome of the ITT (sensi-
tivity and specificity of 100%, area under the ROC curve of 1)
(Fig. 2A).
In the age group between 31 and 50 yr, similar z-scores were
found in individualswith normal and insufficientHPAaxis (0.88
and 0.72, P  0.75) (Fig. 1), and the prognostic value of the
z-score was low (area under the ROC curve 0.57) (Fig. 2A). In
individuals older than 50 yr, the z-score was again significantly
lower in individualswithaninsufficientHPAaxis thaninthosewith
anormalHPAfunction(1.62vs.0.56,P0.02) (Fig.1).Thearea
under the ROC curve of the corresponding ROC curve was 0.77,
and a cutoff value for the z-score at1.42 correctly predicted the
outcome of the ITT in 70% of the cases.
Separate analysis of individualswith apituitarymacroadenoma
revealed a significantly lower z-score if HPA axis was insufficient
than if it was normal (1.73 vs. 0.61, P 0.003) (Fig. 1). The
area under the corresponding ROC curve was 0.82 (Fig. 2B) and a
z-score below 2.0 had a specificity of 100%, whereas a z-score
above 0.5 had a sensitivity of 100% in predicting outcome of ITT.
The z-score had a lower prognostic value in individuals without a
pituitary adenoma (area under the ROC curve 0.71) (Fig. 2B). A
specificity of 100% was reached with a z-score below 2.5,
whereas sensitivity was 100% with a z-score above 2.2.
Discussion
The findingsof thepresent study in individualswith suspected
insufficiency of the HPA axis are 2-fold: 1) the age- and gender-
specific z-score for DHEA-S is lower in individuals with HPA
insufficiency than in those with a normal HPA function; and 2)
there is some evidence that a z-score forDHEA-S is of prognostic
value in predicting HPA function in younger individuals as well
as in patients with a pituitary macroadenoma.
To the best of our knowledge, this is the first study assessing the
diagnostic value of DHEA-S on HPA function using an age- and
gender-specific z-score in a mixed population of individuals with
andwithout a pituitary lesion.Half of the patients in our study had
a pituitary tumor, but the incidence of adenoma was comparable
within each age group. Together with the fact that indications for
testing were generally comparable throughout age-groups, con-
founding by indication is unlikely to have occurred. An earlier re-
port in a similar number of patients comparing DHEA-S with ITT
was limited to patients with large pituitary adenomas exclusively
(3). The authors of this study reported an excellent diagnostic per-
formance ofDHEA-Swith an area under the ROC curve of almost
1. In accordancewith this report,we found a z-score ofDHEA-S to
have an acceptable prognostic value in the presence of a pituitary
macroadenoma, although in our study, the area under the ROC
curve was lower. Potential explanations for these differential find-
ingsare3-fold: first, incontrast tothestudyofNasrallahandArafah
(3), the patients in the present study were all tested after pituitary
surgery. Noteworthy, it was shown before that HPA function can
berestoredafter surgical treatmentofmacroadenoma(14). Second,
NasrallahandArafahuseda lowercutoffvalue forcortisol todefine
HPA integrity (510 vs. 550 nmol/liter).We additionally performed
a sensitivity analysis using the lower value and found results unaf-
fected (data not shown). Third, we found some evidence that a
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FIG. 1. Box plots of age- and gender-specific z-scores of DHEA-S for three age groups (30 yr, 30–50 yr, 51 yr) and individuals with pituitary macroadenoma and
without pituitary adenoma according to integrity of the HPA axis in ITT; individuals with pituitary microadenoma (n  4) were excluded from the analysis; insufficient
denotes peak level of cortisol in ITT less than 550 nmol/liter; normal denotes peak level of 550 nmol/liter or greater.
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z-score for DHEA-S has an advantage in predicting HPA integrity
in younger individuals. Patients with macroadenoma and insuffi-
cientHPAaxiswere older in the present study than in the report by
Nasrallah andArafah (3), and thismay thereby haveweakened the
prognostic value of DHEA-S in our population.
The age dependency in the diagnostic value of a single biochem-
ical measure on pituitary function is not a unique finding. It was
shown previously that the diagnostic reliability of IGF-I in predict-
ing the integrity of the GH axis is best in young individuals (15).
Higher absolute levels as found in younger individuals might im-
prove the discriminatory power of DHEA-S. Furthermore, it could
be hypothesized that the regulatory influence of nonpituitary fac-
torsonDHEA-Ssecretion(6)mayincreasewithage, therebyfurther
weakening its diagnostic value.
A strength of the present study is the prospective design that
allowed us to simultaneously compare DHEA-S with the ITT, the
gold standard. The calculation of an age- and gender-specific z-
score accounted for the dependency of DHEA-S on these two pa-
rameters. The inclusion of patients with and without pituitary le-
sions enabled us to assess the value of DHEA-S in a population
reflecting daily clinical practice at our endocrine division. Never-
theless, we acknowledge several limitations of our study. First, al-
though in view of the complexity of the ITT, a sample size of 70
individuals can be regarded a considerable number, the statistical
power of subgroup analyses is clearly limited. Therefore, we feel
that especially our findings related to the subgroup of younger pa-
tients have to be considered with particular care. Second, we used
an assay that has a comparably high lower limit of detectability
when compared with other reports (3). However, the cutoff levels
that were found to be of diagnostic value were clearly above the
lower limit of the assay.
Inconclusion, individualswithandwithoutpituitaryadenomasuf-
fering fromHPA insufficiency have lower z-scores for DHEA-S than
those with normal HPA function. We found evidence that a z-score
could be of diagnostic value in assessing HPA integrity, especially in
youngerpatientsaswellaspatientswithpituitarymacroadenoma,but
further studies are needed to consolidate these findings.
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FIG. 2. ROC curves for z-scores of DHEA-S according to age group (group 1,
30 yr; group 2, 31–50 yr; group 3, 51 yr) (A) and according to presence or
absence of pituitary macroadenoma (B); the curves are drawn based on the
results of the ITT as the reference. AUC, Area under the ROC curve.
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